An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 conditions characterized by inflammation and fibrosis of the lung interstitium, leading to progressive dyspnea and cough.
Etiology and Classification
ILDs can be idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF). Other forms include nonspecific interstitial pneumonia and sarcoidosis.
Clinical Manifestations and Diagnosis
Patients typically present with progressive dyspnea and dry cough. Physical examination may reveal crackles and clubbing. High-resolution CT is the gold standard for diagnosis. Pulmonary function tests show a restrictive pattern and reduced diffusion capacity.
Treatment and Prognosis
Treatment is largely supportive, including oxygen therapy and pulmonary rehabilitation. Antifibrotic drugs like pirfenidone and nintedanib are approved for IPF. Prognosis varies widely, with IPF having a median survival of 2-3 years post-diagnosis.
Conclusion
ILDs are complex disorders requiring a thorough understanding for effective management. Further research is needed to develop more effective treatments and improve patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge